Artusi CA, Balestrino R, Imbalzano G, et al. - Considering that while levodopa/carbidopa intestinal infusion (LCIG) has shown sustained effectiveness on motor fluctuations of Parkinson disease (PD), there is a shortage of LCIG mortality studies, researchers analyzed mortality and its predictors in a cohort of 105 PD patients treated with LCIG for over 10 years. Included were 98 advanced PD patients treated with LCIG. Data reported that 34.7% of patients died at a mean age of 74.7 years during follow-up, with a mean survival time of 4.6 years from the start of LCIG and 18 years from the beginning of PD. No connection was found between serious adverse events or LCIG treatment duration and mortality and emphasize the significance of cognitive alterations as a mortality predictor of LCIG patients. No survival difference was observed between early drop-out and patients continuing LCIG.